Boundless Bio
BOLD
Boundless Bio (BOLD) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Maintained | Buy | $4.00 from $5.00 | Aug 11, 2025 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $5.00 | Jun 2, 2025 |
| Leerink Partners | Downgraded | Outperform → Market Perform | $3.00 from $15.00 | May 28, 2025 |
| Guggenheim | Downgraded | Buy → Neutral | — | Dec 13, 2024 |
| Piper Sandler | Initiated Coverage | Overweight | $20.00 | Apr 22, 2024 |
| Leerink Partners | Initiated Coverage | Outperform | $25.00 | Apr 22, 2024 |
| Guggenheim | Initiated Coverage | Buy | $24.00 | Apr 22, 2024 |
Frequently asked questions
What is the latest analyst rating on BOLD?
On Aug 11, 2025, HC Wainwright & Co. maintained Boundless Bio at Buy with a price target of $4.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.